日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era

弥合范式差异，塑造可切除胃癌的未来：MATTERHORN 试验后时代的叙述性回顾

期刊:Gastroenterology Report
影响因子:4.2
doi:10.1093/gastro/goag010
Okemoto, Dai; Nakayama, Izuma; Shitara, Kohei
胃癌
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer

基于拷贝数的癌基因优势可能提示 HER2 阳性胃癌中 ERBB2 依赖性和曲妥珠单抗反应

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-026-01204-5
Wakatsuki, Takeru; Yamamoto, Noriko; Ishizuka, Naoki; Hironaka, Shuichi; Minashi, Keiko; Kadowaki, Shigenori; Hirano, Hidekazu; Shoji, Hirokazu; Yamaguchi, Toshifumi; Chin, Keisho; Ogura, Mariko; Nakayama, Izuma; Osumi, Hiroki; Ueki, Arisa; Kitano, Shigehisa; Boku, Narikazu; Yamaguchi, Kensei; Takahari, Daisuke
胃癌
肿瘤
HER2
肿瘤免疫
ERBB2
发表日期：2026
文献求助 收藏

CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives

CLDN18.2在胃癌中的作用：当前治疗现状及未来展望

期刊:Journal of Gastric Cancer
影响因子:3.8
doi:10.5230/jgc.2026.26.e10
Zhang, Fei; Okazaki, Ukyo; Nakayama, Izuma; Shitara, Kohei
胃癌
CLDN1
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies

对靶向 Claudin 18.2 的免疫疗法的靶内/脱靶毒性进行建模和分析

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-65148-6
Carstens, Elizabeth J; Takahashi, Kazuki; Sakamoto, Naoya; De Vizio, Martina; Morgado, Micaela; Nikkhoi, Shahryar Khoshtinat; Mangipudi, Abhishek; Nguyen, Canh Hiep; Weltzin, Tate; Nakayama, Izuma; Lv, Qiang; Zeng, Jue; Nie, Cui; Deng, Changjing; Wang, Xiaoxiao; Liu, Lile; Klempner, Samuel J; Ramasubramanian, Anusuya; Nowak, Jonathan A; Aguirre, Andrew J; Shitara, Kohei; Smith, Eric L
毒理研究
免疫/内分泌
发表日期：2025
文献求助 收藏

Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors

局部晚期胃食管癌和胃癌术前氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛疗效的预后指标：整合生物标志物分析和临床病理因素

期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO-24-00925
Jubashi, Amane; Nakayama, Izuma; Sakamoto, Naoya; Takei, Shogo; Matsubara, Yuki; Miyashita, Yu; Sato, Seiya; Ushiyama, Shinpei; Kobayashi, Akinori; Okazaki, Ukyo; Okemoto, Dai; Yamamoto, Kazumasa; Mishima, Saori; Kotani, Daisuke; Kawazoe, Akihito; Hashimoto, Tadayoshi; Nakamura, Yoshiaki; Kuboki, Yasutoshi; Bando, Hideaki; Kojima, Takashi; Yoshino, Takayuki; Kuwata, Takeshi; Sato, Kazuma; Fujita, Takeo; Yoshida, Mitsumasa; Yura, Masahiro; Kinoshita, Takahiro; Shitara, Kohei
胃癌
食管癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Clinical Significance of Extrachromosomal DNA in FGFR2-Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience

FGFR2扩增型胃癌中染色体外DNA的临床意义：来自临床经验的治疗启示

期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO-25-00033
Aoki, Yu; Hashimoto, Tadayoshi; Takahashi, Nobuyuki; Okunaka, Mashiro; Mishima, Saori; Kotani, Daisuke; Kawazoe, Akihito; Nakamura, Yoshiaki; Nakayama, Izuma; Kuboki, Yasutoshi; Bando, Hideaki; Kojima, Takashi; Nakamura, Nobuyuki; Sakamoto, Naoya; Ishii, Genichiro; Fujisawa, Takao; Yoshino, Takayuki; Arai, Yasuhito; Shibata, Tatsuhiro; Shitara, Kohei
胃癌
肿瘤
FGFR2
肿瘤免疫
发表日期：2025
文献求助 收藏

Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer

曲妥珠单抗德鲁替康治疗HER2阳性胃癌或胃食管交界癌的疗效和安全性预后及预测因素

期刊:Gastric Cancer
影响因子:5.1
doi:10.1007/s10120-024-01560-z
Jubashi, Amane; Nakayama, Izuma; Koganemaru, Shigehiro; Sakamoto, Naoya; Oda, Shioto; Matsubara, Yuki; Miyashita, Yu; Sato, Seiya; Ushiyama, Shinpei; Kobayashi, Akinori; Okazaki, Ukyo; Okemoto, Dai; Yamamoto, Kazumasa; Mishima, Saori; Kotani, Daisuke; Kawazoe, Akihito; Hashimoto, Tadayoshi; Nakamura, Yoshiaki; Kuboki, Yasutoshi; Bando, Hideaki; Kojima, Takashi; Yoshino, Takayuki; Miyaaki, Hisamitsu; Nakao, Kazuhiko; Shitara, Kohei
胃癌
肿瘤
肿瘤免疫
HER2
发表日期：2025
文献求助 收藏

Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023

调查免疫疗法在2011年至2023年间对HER2阴性晚期胃癌患者的真实世界治疗中的作用

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359251322670
Shimozaki, Keitaro; Ooki, Akira; Yoshino, Koichiro; Tamba, Mikako; Udagawa, Shohei; Osumi, Hiroki; Fukuoka, Shota; Nakayama, Izuma; Wakatsuki, Takeru; Ogura, Mariko; Takahari, Daisuke; Shinozaki, Eiji; Chin, Keisho; Yamaguchi, Kensei
胃癌
肿瘤
肿瘤免疫
HER2
免疫/内分泌
发表日期：2025
文献求助 收藏

Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond

靶向非致癌驱动因子治疗胃癌的新证据：Claudin18.2 及其他

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359251344804
Yamamoto, Kazumasa; Nakayama, Izuma; Shitara, Kohei
胃癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)

循环肿瘤DNA在HER2阳性晚期胃癌中的临床意义：一项双重HER2和PD-1靶向治疗Ib期试验的合作研究（Ni-High）

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359251367344
Osumi, Hiroki; Wakatsuki, Takeru; Ooki, Akira; Chin, Keisho; Shoji, Hirokazu; Ogura, Mariko; Nakayama, Izuma; Yamamoto, Noriko; Hirano, Hidekazu; Hara, Hiroki; Minashi, Keiko; Shinozaki, Eiji; Kato, Ken; Ishizuka, Naoki; Kitano, Shigehisa; Takeuchi, Kengo; Boku, Narikazu; Yamaguchi, Kensei; Takahari, Daisuke
胃癌
肿瘤
HER2
肿瘤免疫
PD-1
发表日期：2025
文献求助 收藏